跳至主要内容
临床试验/NCT05216016
NCT05216016已完成不适用

Minnesota Retaining Employment and Talent After Injury/Illness Network Phase 2 RETAIN

Mayo Clinic2 个研究点 分布在 1 个国家目标入组 3,414 人开始时间: 2021年12月23日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
Mayo Clinic
入组人数
3,414
试验地点
2
主要终点
Workers to maintain employment

研究概览

简要总结

MN RETAIN Phase 2 Sub-study is a non-randomized trial to evaluate the impact of RETAIN program expansion and services on workforce retention and reduction of future workplace disability in the state of MN. The program is funded by US Department of Labor (US DOL) and sponsored jointly with the US Social Security Administration. There will be collaboration between partners to implement best practices in early intervention to support injured or ill employees in stay-at-work and return-to-work. MN RETAIN involves a partnership between Mayo Clinic and MN Department of Employment and Economic Development (DEED), MN Department of Labor and Industry (DLI), MN Department of Health (MDH), Workforce Development, Inc. (WDI), and the Governor's Workforce Development Board. MN DEED serves as the main recipient and administrator of the funding within the state with Mayo Clinic, DLI, and WDI, as subrecipients of the grant.

(Effective Date: 12/23/2021-05/16/2024) MN RETAIN Phase 2 : This study is a randomized control trial (RCT) to evaluate the impact of RETAIN program expansion and services on workforce retention and reduction of future workplace disability in the state of MN. The program is funded by US Department of Labor (US DOL) and sponsored jointly with the US Social Security Administration. There will be collaboration between partners to implement best practices in early intervention to support injured or ill employees in stay-at-work and return-to-work. MN RETAIN involves a partnership between Mayo Clinic and MN Department of Employment and Economic Development (DEED), MN Department of Labor and Industry (DLI), MN Department of Health (MDH), Workforce Development, Inc. (WDI), and the Governor's Workforce Development Board. MN DEED serves as the main recipient and administrator of the funding within the state with Mayo Clinic, DLI, and WDI, as subrecipients of the grant. During this Phase: additional collaborators: Mathematica Policy Research

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • > 18-years-old
  • MN Resident
  • Works in MN
  • Employed at the time of enrollment
  • Within 6 months of last day of work
  • Meets one of the following:
  • Provider work restrictions of unable to work for at least 4 weeks
  • Per healthcare team anticipated to be unable to work for at least 4 weeks
  • Employer's inability to accommodate current work restrictions
  • Meets one of the following:
  • Diagnosis of a work related or personal injury or illness that impacts employment
  • Invasive procedure (e.g., surgery) anticipated within the next 4-weeks that impacts employment
  • Documentation of work restrictions (i.e., written note/form documentation in electronic medical record prior to enrollment)

排除标准

  • Legal representation/litigation at the time of enrollment related to a workers' compensation medical condition
  • Does not have the capacity to give appropriate informed consent
  • Employed by a RETAIN healthcare recipient or subrecipient with an existing return to work program for employees (i.e., Mayo Clinic employees)
  • Workers' compensation recipients that have a qualified rehabilitation consultant (QRC) or a disability case manager (DCM)
  • Pending application OR Receiving Social Security Disability Insurance (SSDI) or Supplemental Security Income (SSI)
  • Self-Employed

研究组 & 干预措施

Control Group

No Intervention

Individuals will receive a handout with additional job related services; e.g. Job Accommodation Network.

Intervention Group

Experimental

Individuals will be assigned a dedicated Minnesota RETAIN Return-to-Work Case Manager. Intervention group participants will be referred for additional career and workforce development resources when needed.

干预措施: RETAIN Program (Other)

Sub Study Group

Experimental

Individuals will be assigned a dedicated Minnesota RETAIN Return-to-Work Case Manager. Intervention group participants will be referred for additional career and workforce development resources when needed.

干预措施: RETAIN Program (Other)

结局指标

主要结局

Workers to maintain employment

时间窗: 12 months

Total number of workers employed at the time of program completion and who have maintained employment 12 months after enrollment.

Reduction on work disability at 1 years

时间窗: 1 year

Total number of enrollees that applied for SSDI or SSI during any of the 1 year after enrollment.

Reduction in long term work disability

时间窗: 5 years

Total number of enrollees that applied for SSDI or SSI during any of the 5 year after enrollment.

次要结局

未报告次要终点

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Laura E. Breeher

Principal Investigator

Mayo Clinic

研究点 (2)

Loading locations...

相似试验

已完成
2 期
Randomized phase 2 study comparing maintenance treatments with paclitaxel plus bevacizumab and endocrine agent in patients with inoperable or recurrent breast cancer who received prior endocrine treatment and achieved non progressive disease during induction treatment with paclitaxel plus bevacizumab.Breast cancer
JPRN-UMIN000008955CAPTURE Clinical Trial Group150
进行中(未招募)
1 期
Clinical study to explore the influence of BRAF and PIK3K status on the efficacy of FOLFIRI plus Bevacizumab or Cetuximab, as therapy of patients with KRAS wild-type metastatic colorectal carcinoma and < 3 circulating tumor cells.Metastatic colorectal cancer.MedDRA version: 14.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2012-000840-90-ESGrupo de Tratamiento de los Tumores Digestivos (TTD)240
招募中
2 期
Phase II randomized study to investigate the effectiveness of Hangeshashinto(TJ-14) against chemoradiation-induced oral and pharyngeal mucositishead and neck cancer
JPRN-UMIN000012948Department of Otolaryngolory-Head and Neck Surgery, National Defense Medical College of Japan90
招募中
2 期
A study on the efficacy and safety of cisplatin/etoposide and concomitant radiotherapy in combination with durvalumab, an immunotherapy, in patients with local limited small cell lung cancer
2024-513433-20-00Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR105
尚未招募
2 期
A randomised phase 2 study of carboplatin with oral vinorelbine followed by maintenance therapy with oral vinorelbine or erlotinib in elderly patients with metastatic non-small cell lung cancer.on Small Cell Lung CancerNon Small Cell Lung CancerCancer - Lung - Non small cell
ACTRN12612000473864Southern Health100